The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 01, 2011
Filed:
May. 02, 2008
Joaquim Trias, Millbrae, CA (US);
Colin Hislop, Menlo Park, CA (US);
Paul Truex, Pleasanton, CA (US);
Bernadine Fraser, Sunnyvale, CA (US);
Debra Odink, Oakland, CA (US);
Scott Chadwick, Redwood City, CA (US);
Kenneth Gould, Zionsville, IN (US);
Marian Mosior, Indianapolis, IN (US);
Patrick Eacho, Indianapolis, IN (US);
Joaquim Trias, Millbrae, CA (US);
Colin Hislop, Menlo Park, CA (US);
Paul Truex, Pleasanton, CA (US);
Bernadine Fraser, Sunnyvale, CA (US);
Debra Odink, Oakland, CA (US);
Scott Chadwick, Redwood City, CA (US);
Kenneth Gould, Zionsville, IN (US);
Marian Mosior, Indianapolis, IN (US);
Patrick Eacho, Indianapolis, IN (US);
Anthera Pharmaceuticals, Inc., Hayward, CA (US);
Abstract
Administration of sPLAinhibitors has been found to decrease cholesterol levels, atherosclerotic plaque formation and aortic aneurysm in mice, and to decrease cholesterol and triglyceride levels in humans. Interestingly, administration of sPLAinhibitors was found to decrease cholesterol levels even when the inhibitors were administered only once per day. Therefore, provided herein are methods of treating dyslipidemia, CVD, and conditions associated with CVD such as atherosclerosis and metabolic syndrome, by administering one or more sPLAinhibitors. Significantly, administration of sPLAinhibitors and various compounds used in the treatment of CVD, such as for example statins, resulted in greater decreases in LDL and LDL particle levels in a synergistic manner. In addition, administration of sPLAinhibitors and statins resulted in a synergistic decrease in plaque content. Therefore, also provided herein are compositions comprising one or more sPLAinhibitors and one or more compounds used in the treatment of CVD, such as for example statins, and methods of using these compositions to treat dyslipidemia, CVD, and conditions associated with CVD such as atherosclerosis and metabolic syndrome.